Florian Lordick, Oncologist, Professor of Medicine at University of Leipzig, Head of Medical Oncology, Director of the Comprehensive Cancer Center Central, Germany, shared on LinkedIn:
“LUCERNA – moving the field forward for patients with advanced CLDN18.2-positive and PD-L1-positive gastric cancer.
Exploring the potential of a biomarker-driven combination strategy to further improve outcomes. Exciting to see this trial in progress published in ESMO Gastrointestinal Oncology!”
Title: Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial
Authors: K. Shitara, P. Enzinger, F. Lordick, E. Smyth, S.Y. Rha, E. Van Cutsem, R.-H. Xu, J.H. Strickler, P. Lee, S.J. Klempner
Other articles about gastric cancer and gastroesophageal junction adenocarcinoma on OncoDaily.